Relmada Therapeutics (RLMD) announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market confirming that the Company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD: